Brainstorm Cell Therapeutics (BCLI) Tops Q2 EPS by 3c

Brainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q2 EPS of ($0.04), $0.03 better than the analyst estimate of ($0.07).

For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.

You May Also Be Interested In

• Is Treasury selloff a major issue for stock market bulls?
• Tesla (TSLA) call put ratio 1.2 calls to 1 put with a focus on 1500 contracts of September 100 puts
• Brean Capital Upgrades Columbia Financial Inc (CLBK) to Buy